(ETTX) – Hot FDA News
-
Entasis Therapeutics Holdings Inc. (ETTX) study of sulbactam-durlobactam from Phase 3 ATTACK trial meets primary endpoint
-
Entasis Therapeutics Holdings Inc. (ETTX) Reports Positive Feedback from FDA End-of-Phase 2 Meeting for ETX2514SUL; Sign Rapid Diagnostic Agreement with bioMerieux
Back to ETTX Stock Lookup